Douglas E Gladstone

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies
    Douglas E Gladstone
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Baltimore, MD 21287, USA
    Biol Blood Marrow Transplant 19:647-52. 2013
  2. ncbi request reprint High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis: 2-year follow-up (investigational new drug No. 65863)
    Douglas E Gladstone
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA
    Am J Ther 18:23-30. 2011
  3. pmc The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia
    Douglas E Gladstone
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    Clin Lymphoma Myeloma Leuk 12:132-7. 2012
  4. doi request reprint Hematopoietic stem cell transplantation for chronic lymphocytic leukemia
    Douglas E Gladstone
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
    Curr Opin Oncol 24:176-81. 2012
  5. pmc High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas
    Douglas E Gladstone
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    Leuk Lymphoma 52:2076-81. 2011
  6. pmc Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia
    Douglas E Gladstone
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    Leuk Lymphoma 52:1873-81. 2011
  7. pmc Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis
    Jennifer A Kanakry
    Division of Hematology, School of Medicine, Johns Hopkins University, Baltimore, Maryland
    Biol Blood Marrow Transplant 19:1514-7. 2013
  8. pmc Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma
    Jennifer A Kanakry
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland
    Biol Blood Marrow Transplant 19:602-6. 2013
  9. doi request reprint Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia
    Yvette L Kasamon
    Johns Hopkins University, Baltimore, MD, USA
    Leuk Lymphoma 54:483-90. 2013
  10. pmc Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Clin Cancer Res 18:6723-31. 2012

Collaborators

Detail Information

Publications18

  1. pmc Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies
    Douglas E Gladstone
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Baltimore, MD 21287, USA
    Biol Blood Marrow Transplant 19:647-52. 2013
    ....
  2. ncbi request reprint High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis: 2-year follow-up (investigational new drug No. 65863)
    Douglas E Gladstone
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA
    Am J Ther 18:23-30. 2011
    ..The most appropriate candidates for HDC, its duration of benefit, and the potential need for prophylactic preventative immune manipulation after HDC all require further investigation...
  3. pmc The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia
    Douglas E Gladstone
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    Clin Lymphoma Myeloma Leuk 12:132-7. 2012
    ..06). These data suggest that IGHV mutational status has prognostic relevance even in patients with CLL who are defined as poor risk by genomic FISH analysis...
  4. doi request reprint Hematopoietic stem cell transplantation for chronic lymphocytic leukemia
    Douglas E Gladstone
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
    Curr Opin Oncol 24:176-81. 2012
    ..Now in the era of improved conventional treatment and better prognostication of long-term outcome, a review of autologous and allogeneic HSCT in CLL treatment is warranted...
  5. pmc High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas
    Douglas E Gladstone
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    Leuk Lymphoma 52:2076-81. 2011
    ..The 5-year EFS and OS for patients with MCL were 39% and 62%, respectively. This low-toxicity therapeutic approach obviates the need for stem cell products and establishes a platform for future therapies...
  6. pmc Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia
    Douglas E Gladstone
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    Leuk Lymphoma 52:1873-81. 2011
    ..001), to receive treatment (p = 0.02), and to have a shorter overall survival (p = 0.13) than the 34 mutated patients. These data suggest that del(13q) conveys an indolent course only in patients with IGHV-mutated CLL...
  7. pmc Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis
    Jennifer A Kanakry
    Division of Hematology, School of Medicine, Johns Hopkins University, Baltimore, Maryland
    Biol Blood Marrow Transplant 19:1514-7. 2013
    ..No cases of PTLD occurred during the first year after allo-BMT in this series. PTLD is a rare occurrence after allo-BMT using PTCy, even in high-risk alternative donor transplantations. ..
  8. pmc Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma
    Jennifer A Kanakry
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland
    Biol Blood Marrow Transplant 19:602-6. 2013
    ..AlloBMT may be appropriate in first remission in select high-risk cases...
  9. doi request reprint Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia
    Yvette L Kasamon
    Johns Hopkins University, Baltimore, MD, USA
    Leuk Lymphoma 54:483-90. 2013
    ..Seventeen (81%) received intensification (median 30 days to intensification). Brief, anthracycline-sparing, intensive cyclophosphamide (BASIC) therapy yields durable remissions in poorer-risk BL/atypical BL...
  10. pmc Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Clin Cancer Res 18:6723-31. 2012
    ..To extend these findings to the clinical setting, we have conducted a phase I study of cytarabine and SCH 900776...
  11. pmc HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation
    Amer M Zeidan
    The Sidney Kimmel Comprehensive Cancer Center, Department of Oncology at the Johns Hopkins University, Baltimore, Maryland
    Biol Blood Marrow Transplant 20:314-8. 2014
    ..8 (mean, 22.5; range, .4 to 94) months. At last follow-up, 8 responders were alive in CR; 6 for over a year. HaploDLI for relapse after haploBMT is associated with acceptable toxicities and can result in durable responses...
  12. pmc Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias
    Amer M Zeidan
    Division of Hematologic Malignancies, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Br J Haematol 158:198-207. 2012
    ..In summary, the CLO-CYx4 regimen was well tolerated and had activity in patients with RRAL, especially relapsed ALL. Therefore, CLO-CYx4 can be considered a salvage therapy for adults with RRALs, and warrants further investigations...
  13. doi request reprint Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro
    Robert L Dilley
    Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA
    Leuk Res 38:411-7. 2014
    ..Our results provide rationale for further exploration of the combination of a PARP inhibitor and DNA damaging agents as a novel therapeutic strategy in CLL. ..
  14. pmc Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
    Yvette L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    Blood 119:4129-32. 2012
    ..Persistence of detectable circulating clonotypic B cells was associated with a greater relapse frequency (P < .05). Rituximab-ABVD and clonotypic B cells warrant additional study in classical Hodgkin lymphoma...
  15. pmc Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance
    Daniel M Harrison
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Mult Scler 18:202-9. 2012
    ..The long-term benefit of this stabilization followed by conventional therapy has not been explored...
  16. doi request reprint Maintaining hemostasis in acquired von Willebrand syndrome: a review of intravenous immunoglobulin and the importance of rituximab dose scheduling
    Jennifer A Kanakry
    Department of Hematology, The Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Transfusion 53:1730-5. 2013
    ..Herein, we provide an updated review of the use of IVIG and rituximab for AVWS and present rituximab maintenance as an effective and durable strategy for the management of these patients...
  17. pmc Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231 1000, USA
    Haematologica 97:1736-42. 2012
    ..6 months...
  18. ncbi request reprint The role of growth factors in the activity of pharmacological differentiation agents
    William H Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cell Growth Differ 13:275-83. 2002
    ..These data suggest that many pharmacological differentiating agents require both cell cycle arrest and lineage-specific growth factors for full activity and may explain why these agents have demonstrated only limited clinical efficacy...